Aim: To compare refractive error changes in retinopathy of prematurity (ROP) patients treated with diode and red lasers. Methods: A randomized double-masked clinical trial was performed, and infants with threshold or prethreshold type 1 ROP were assigned to red or diode laser groups. Gestational age, birth weight, pretreatment cycloplegic refraction, time of treatment, disease stage, zone and disease severity were recorded. Patients received either red or diode laser treatment and were regularly followed up for retina assessment and refraction. The information at month 12 of corrected age was considered for comparison. Results: One hundred and fifty eyes of 75 infants were enrolled in the study. Seventy-four eyes received diode and 76 red laser therapy. The mean gestational age and birth weight of the infants were 28.6 ± 3.2 weeks and 1,441 ± 491 g, respectively. The mean baseline refractive error was +2.3 ± 1.7 dpt. Posttreatment refraction showed a significant myopic shift (mean 2.6 ± 2.0 dpt) with significant difference between the two groups (p < 0.001). There was a greater myopic shift among children with zone I and diode laser treatment (mean 6.00 dpt) and a lesser shift among children with zone II and red laser treatment (mean 1.12 dpt). The linear regression model, using the generalized estimating equation method, showed that the type of laser used has a significant effect on myopic shift even after adjustment for other variables. Conclusion: Myopic shift in laser-treated ROP patients is related to the type of laser used and the involved zone. Red laser seems to cause less myopic shift than diode laser, and those with zone I involvement have a greater myopic shift than those with ROP in zone II.

1.
Holmstrom GE, Kallen K, Hellstrom A, et al: Ophthalmologic outcome at 30 months' corrected age of a prospective Swedish cohort of children born before 27 weeks of gestation: the Extremely Preterm Infants in Sweden Study. JAMA Ophthalmol 2014;132:182-189.
2.
Haines L, Fielder AR, Baker H, Wilkinson AR: UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome. Arch Dis Child Fetal Neonatal Ed 2005;90:F240-F244.
3.
Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG: An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAPOS 2012;16:501-507.
4.
Hreinsdottir J, Ewald U, Strand Brodd K, Ornkloo H, von Hofsten C, Holmstrom G: Ophthalmological outcome and visuospatial ability in very preterm children measured at 2.5 years corrected age. Acta Paediatr 2013;102:1144-1149.
5.
Gilbert C: Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84:77-82.
6.
Fielder A, Blencowe H, O'Connor A, Gilbert C: Impact of retinopathy of prematurity on ocular structures and visual functions. Arch Dis Child Fetal Neonatal Ed 2015;100:F179-F184.
7.
Lue CL, Hansen RM, Reisner DS, Findl O, Petersen RA, Fulton AB: The course of myopia in children with mild retinopathy of prematurity. Vision Res 1995;35:1329-1335.
8.
Quinn GE, Dobson V, Kivlin J, et al: Prevalence of myopia between 3 months and 5 1/2 years in preterm infants with and without retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1998;105:1292-1300.
9.
Chen TC, Tsai TH, Shih YF, et al: Long-term evaluation of refractive status and optical components in eyes of children born prematurely. Invest Ophthalmol Vis Sci 2010;51:6140-6148.
10.
Yang CS, Wang AG, Shih YF, Hsu WM: Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Acta Ophthalmol 2013;91:e276-e282.
11.
Cook A, White S, Batterbury M, Clark D: Ocular growth and refractive error development in premature infants with or without retinopathy of prematurity. Invest Ophthalmol Vis Sci 2008;49:5199-5207.
12.
Baker PS, Tasman W: Myopia in adults with retinopathy of prematurity. Am J Ophthalmol 2008;145:1090-1094.
13.
Dogra MR, Narang S, Biswas C, Gupta A, Narang A: Threshold retinopathy of prematurity: ocular changes and sequelae following cryotherapy. Indian J Ophthalmol 2001;49:97-101.
14.
Shalev B, Farr AK, Repka MX: Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: seven-year outcome. Am J Ophthalmol 2001;132:76-80.
15.
The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991-999.
16.
Good WV: Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004;102:233-248; discussion 248-250.
17.
Gonzalez VH, Giuliari GP, Banda RM, Guel DA, Wingard M: Confluent laser photocoagulation for the treatment of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2010;47:81-85; quiz 86-87.
18.
O'Connor AR, Stephenson TJ, Johnson A, Tobin MJ, Ratib S, Fielder AR: Change of refractive state and eye size in children of birth weight less than 1,701 g. Br J Ophthalmol 2006;90:456-460.
19.
Ozdemir M, Koylu S: Ocular growth and morbidity in preterm children without retinopathy of prematurity. Jpn J Ophthalmol 2009;53:623-628.
20.
Hsieh CJ, Liu JW, Huang JS, Lin KC: Refractive outcome of premature infants with or without retinopathy of prematurity at 2 years of age: a prospective controlled cohort study. Kaohsiung J Med Sci 2012;28:204-211.
21.
McLoone EM, O'Keefe M, McLoone SF, Lanigan BM: Long-term refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity. J AAPOS 2006;10:454-459.
22.
Ratanasukon M, Visaetsilpanonta S, Tengtrisorn S, Kittantong A, Hirunpat C: Outcomes of scleral buckling for stage 4 retinopathy of prematurity in Thai children. J Med Assoc Thai 2006;89:1659-1664.
23.
Quinn GE, Dobson V, Davitt BV, et al: Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age. J AAPOS 2013;17:124-128.
24.
Sahni J, Subhedar NV, Clark D: Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months. Br J Ophthalmol 2005;89:154-159.
25.
Warrasak S, Nawarutkulchai S, Sinsawat P: Functional result and visual outcome in early versus conventional treatment of retinopathy of prematurity. J Med Assoc Thai 2012;95(suppl 4):S107-S115.
26.
Chew C, Rahman RA, Shafie SM, Mohamad Z: Comparison of mydriatic regimens used in screening for retinopathy of prematurity in preterm infants with dark irides. J Pediatr Ophthalmol Strabismus 2005;42:166-173.
27.
Twelker JD, Mutti DO: Retinoscopy in infants using a near noncycloplegic technique, cycloplegia with tropicamide 1%, and cycloplegia with cyclopentolate 1%. Optom Vis Sci 2001;78:215-222.
28.
Derinoz O, Er A: Inability to walk, disequilibrium, incoherent speech, disorientation following the instillation of 1% cyclopentolate eyedrops: case report. Pediatr Emerg Care 2012;28:59-60.
29.
Derinoz O, Emeksiz HC: Use of physostigmine for cyclopentolate overdose in an infant. Pediatrics 2012;130:e703-e705.
30.
Buyukcam A, Celik HT, Korkmaz A, Yurdakok M: Myoclonic seizure due to cyclopentolate eye drop in a preterm infant. Turk J Pediatr 2012;54:419-420.
31.
Mills MD: Evaluating the Cryotherapy for Retinopathy of Prematurity Study (CRYO-ROP). Arch Ophthalmol 2007;125:1276-1281.
32.
Gnanaraj L, Brennan R, Cottrell DG: Retinopathy of prematurity in practice. 2. Long-term results following treatment for threshold disease. Eye (Lond) 2003;17:189-193.
33.
DeJonge MH, Ferrone PJ, Trese MT: Diode laser ablation for threshold retinopathy of prematurity: short-term structural outcome. Arch Ophthalmol 2000;118:365-367.
34.
Clark D, Mandal K: Treatment of retinopathy of prematurity. Early Hum Dev 2008;84:95-99.
35.
Sanghi G, Dogra MR, Vinekar A, Gupta A: Frequency-doubled Nd:YAG (532 nm green) versus diode laser (810 nm) in treatment of retinopathy of prematurity. Br J Ophthalmol 2010;94:1264-1265.
36.
Johnson MW, Hassan TS, Elner VM: Laser photocoagulation of the choroid through experimental subretinal hemorrhage. Arch Ophthalmol 1995;113:364-370.
37.
Dyer DS, Bressler SB, Bressler NM: The role of laser wavelength in the treatment of vitreoretinal diseases. Curr Opin Ophthalmol 1999;5:35-43.
38.
Khairallah M, Brahim R, Allagui M, Chachia N: Comparative effects of argon green and krypton red laser photocoagulation for patients with diabetic exudative maculopathy. Br J Ophthalmol 1996;80:319-322.
39.
Ghassemi F, Ebrahimiadib N, Roohipoor R, Moghimi S, Alipour F: Nerve fiber layer thickness in eyes treated with red versus green laser in proliferative diabetic retinopathy: short-term results. Ophthalmologica 2013;230:195-200.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.